Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

AC Immune (ACIU) Revenue (2016 - 2026)

AC Immune has reported Revenue over the past 10 years, most recently at $1.4 million for Q1 2026.

  • Quarterly Revenue rose 29.77% to $1.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Mar 2026, down 85.87% year-over-year, with the annual reading at $4.5 million for FY2025, 85.66% down from the prior year.
  • Revenue was $1.4 million for Q1 2026 at AC Immune, up from $422895.4 in the prior quarter.
  • Over five years, Revenue peaked at $29.4 million in Q3 2024 and troughed at $422895.4 in Q4 2025.
  • The 4-year median for Revenue is $1.3 million (2024), against an average of $4.6 million.
  • The largest YoY upside for Revenue was 107.65% in 2025 against a maximum downside of 96.01% in 2025.
  • A 4-year view of Revenue shows it stood at $4.0 million in 2022, then tumbled by 67.86% to $1.3 million in 2024, then plummeted by 67.42% to $422895.4 in 2025, then skyrocketed by 237.9% to $1.4 million in 2026.
  • Per Business Quant, the three most recent readings for ACIU's Revenue are $1.4 million (Q1 2026), $422895.4 (Q4 2025), and $1.2 million (Q3 2025).